EUVIMEDEUVIMED entdecken
Crossref

Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2

Juan M. Maldonado, Christophe De Block, Juan Frias, Clare J. Lee, Katelyn Brown, Hui Wang, Melissa K. Thomas, Thomas Forst

Diabetologie und Stoffwechsel · 01.04.2024 · 19 (S 01 S 01) · S78

DOI: 10.1055/s-0044-1785390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.04.2024. Verfasst von Juan M. Maldonado und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Is tirzepatide (TZP 5, 10, 15mg) efficacious in reducing HbA1c and body weight (BW) compared to placebo (PBO) and semaglutide 1mg (SEMA) in people with type 2 diabetes (T2D) irrespective of baseline beta-cell function?

Method

Exploratory post-hoc analyses of people with T2D controlled by diet and exercise [SURPASS 1 (PBO)] and Metformin [SURPASS-2 (SEMA)] examined changes from baseline in HbA1c and BW at 40 weeks across HOMA2-B (C-peptide) and HOMA2-IR (insulin) quartiles (Q) from low (lower beta-cell function/insulin resistance) (Q1) to high (Q4) as assessed by mixed model repeated measures (MMRM).

Results

HbA1c reductions were greater with all TZP doses than PBO or SEMA within each HOMA2-B and HOMA2-IR baseline Q. HbA1c reductions were largest in people within HOMA-2B Q1, yet similar across all HOMA2-IR Qs. BW reductions were greater across Qs with all TZP doses (ranging from 6%-14%) than PBO (up to 2%) or SEMA (up to 7%).

Conclusion

TZP was more efficacious than PBO or SEMA in reducing HbA1c and BW across a spectrum of pancreatic beta-cell function, notably achieving greater glycemic improvement in people with markers of diminished pancreatic beta cell function at baseline. Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Maldonado, J. M., Block, C. D., Frias, J., Lee, C. J., Brown, K., Wang, H., Thomas, M. K., & Forst, T. (2024). Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2. Diabetologie und Stoffwechsel, 19(S 01 S 01), S78. https://doi.org/10.1055/s-0044-1785390

Vancouver

Maldonado JM, Block CD, Frias J, Lee CJ, Brown K, Wang H, et al. Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2. Diabetologie und Stoffwechsel. 2024;19(S 01 S 01):S78. doi:10.1055/s-0044-1785390

BibTeX
@article{Maldonado2024,
  author = {Maldonado, Juan M. and Block, Christophe De and Frias, Juan and Lee, Clare J. and Brown, Katelyn and Wang, Hui and Thomas, Melissa K. and Forst, Thomas},
  title = {Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2},
  journal = {Diabetologie und Stoffwechsel},
  year = {2024},
  volume = {19},
  number = {S 01 S 01},
  pages = {S78},
  doi = {10.1055/s-0044-1785390}
}
Kostenlos starten →